Beauty Farm Medical and Health Industry Inc. completed an on-market repurchase of 58,500 ordinary shares on 1 April 2026, paying an aggregate HKD 1.17 million. The shares were acquired at prices ranging from HKD 19.92 to HKD 20.48, with a volume-weighted average cost of HKD 20.0079 per share.

Following the transaction, issued shares outstanding (excluding treasury shares) fell 0.0234% from 250.44 million to 250.38 million. Treasury stock increased from 1.16 million to 1.21 million shares, while total issued shares remained unchanged at 251.59 million because the repurchased shares are being held in treasury rather than cancelled.

The purchase was executed under the buyback mandate approved on 27 June 2025, which authorises the company to repurchase up to 23.58 million shares. To date, Beauty Farm Medical has repurchased 1.21 million shares under this mandate, representing 0.5146% of the issued share base (235.80 million shares) at the time the mandate was granted.

A 30-day moratorium on new share issues or sales of treasury shares is in effect until 1 May 2026, in accordance with Hong Kong Listing Rule 10.06(3)(a).

All repurchase procedures were confirmed to be in compliance with Hong Kong listing regulations and the company’s internal authorisations.